Published in Antimicrob Agents Chemother on February 01, 1989
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother (1991) 4.35
Linkage map of Escherichia coli K-12, edition 10: the traditional map. Microbiol Mol Biol Rev (1998) 4.18
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (1996) 3.86
Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother (2001) 3.62
Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother (2000) 3.27
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1996) 2.91
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrob Agents Chemother (1991) 2.82
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1993) 2.68
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother (1998) 2.59
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1990) 2.43
Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1996) 2.34
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother (1997) 2.33
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother (1993) 2.04
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother (1999) 1.99
Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother (1995) 1.72
DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance-determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A. Antimicrob Agents Chemother (2002) 1.72
Characterization of high-level quinolone resistance in Campylobacter jejuni. Antimicrob Agents Chemother (1991) 1.55
Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob Agents Chemother (1989) 1.55
Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol (1996) 1.50
Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Antimicrob Agents Chemother (1991) 1.42
Mechanisms of resistance to quinolones. Drugs (1993) 1.41
Broad-host-range gyrase A gene probe. Antimicrob Agents Chemother (1990) 1.38
Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother (1999) 1.34
Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother (1991) 1.24
Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob Agents Chemother (1992) 1.21
Mechanism of action of and resistance to quinolones. Microb Biotechnol (2008) 1.16
Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother (1995) 1.13
Type II topoisomerase quinolone resistance-determining regions of Aeromonas caviae, A. hydrophila, and A. sobria complexes and mutations associated with quinolone resistance. Antimicrob Agents Chemother (2002) 1.11
Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci U S A (1992) 1.10
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother (2012) 1.06
Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones. Antimicrob Agents Chemother (2008) 1.05
In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium. Antimicrob Agents Chemother (1992) 0.96
Effect of pyrimido[1,6-a]benzimidazoles, quinolones, and Ca2+ on the DNA gyrase-mediated cleavage reaction. Antimicrob Agents Chemother (1995) 0.93
Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG. Antimicrob Agents Chemother (2009) 0.92
Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA. Antimicrob Agents Chemother (1991) 0.91
Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol (2010) 0.88
Alterations of gyrA, gyrB, and parC and Activity of Efflux Pump in Fluoroquinolone-resistant Acinetobacter baumannii. Osong Public Health Res Perspect (2011) 0.88
Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol (1994) 0.87
Implications of amino acid substitutions in GyrA at position 83 in terms of oxolinic acid resistance in field isolates of Burkholderia glumae, a causal agent of bacterial seedling rot and grain rot of rice. Appl Environ Microbiol (2004) 0.86
Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. Antimicrob Agents Chemother (2014) 0.81
The threat of multiresistant microorganisms. Eur J Clin Microbiol Infect Dis (1993) 0.79
A population genomics approach to exploiting the accessory 'resistome' of Escherichia coli. Microb Genom (2017) 0.75
Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol (1969) 8.78
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother (1984) 6.81
Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95
Studies on the mechanism of action of nalidixic acid. Antimicrob Agents Chemother (1973) 5.64
Hybrid plasmids containing an active thymidine kinase gene of Herpes simplex virus 1. Nucleic Acids Res (1979) 5.55
Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity. Proc Natl Acad Sci U S A (1978) 5.33
New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. J Bacteriol (1981) 3.65
Mutation affecting resistance of Escherichia coli K12 to nalidixic acid. J Gen Microbiol (1985) 1.89
Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers. Antimicrob Agents Chemother (1987) 1.74
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Antisense transcription in the mammalian transcriptome. Science (2005) 15.69
Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther (2000) 12.54
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell (1999) 9.05
DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 7.85
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature (1979) 6.56
Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01
Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95
Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell (2001) 5.39
Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (2001) 5.07
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother (1989) 4.79
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer (2006) 4.46
Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science (1993) 4.39
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci U S A (1993) 4.35
Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature (1998) 4.18
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
New ages for the last Australian megafauna: continent-wide extinction about 46,000 years ago. Science (2001) 3.91
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64
Signalling from endoplasmic reticulum to nucleus: transcription factor with a basic-leucine zipper motif is required for the unfolded protein-response pathway. Genes Cells (1996) 3.58
Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord (2006) 3.55
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med (2000) 3.44
On the process of cellular division in Escherichia coli: nucleotide sequence of the gene for penicillin-binding protein 3. Mol Gen Genet (1983) 3.43
Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett (1996) 3.40
A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut (2004) 3.35
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A (1987) 3.32
Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol (2001) 3.26
Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med (2001) 3.23
Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol (1984) 3.20
Light-dependent translocation of a phytochrome B-GFP fusion protein to the nucleus in transgenic Arabidopsis. J Cell Biol (1999) 3.14
Noggin is a mesenchymally derived stimulator of hair-follicle induction. Nat Cell Biol (1999) 2.99
Diet-dependent shifts in the bacterial population of the rumen revealed with real-time PCR. Appl Environ Microbiol (2001) 2.98
The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell (2001) 2.97
Mutations in the Drosophila dTAK1 gene reveal a conserved function for MAPKKKs in the control of rel/NF-kappaB-dependent innate immune responses. Genes Dev (2001) 2.96
Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (1999) 2.96
Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut (1998) 2.84
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science (1994) 2.78
Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science (1987) 2.75
Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology (1996) 2.59
Self-organization of microtubule asters induced in Xenopus egg extracts by GTP-bound Ran. Science (1999) 2.59
Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol (1999) 2.55
In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos. Immunity (1998) 2.54
Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol (2003) 2.52
Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis (1999) 2.52
The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol (1996) 2.50
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
Nucleotide sequence of the asnA gene coding for asparagine synthetase of E. coli K-12. Nucleic Acids Res (1981) 2.42
Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother (1990) 2.42
Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med (2000) 2.37
Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord (2006) 2.28
Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat Genet (1997) 2.28
Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature (1991) 2.28
Inflammatory pseudotumor of the liver. Clinicopathologic study and review of the literature. Cancer (1990) 2.26
Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut (1999) 2.25
Host range of human T-cell leukemia virus type I analyzed by a cell fusion-dependent reporter gene activation assay. Virology (1999) 2.21
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest (1996) 2.21
Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. Development (2001) 2.19
Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem (1999) 2.19
Genetic mutations in exons 3 and 4 of the pancreatic secretory trypsin inhibitor in patients with pancreatitis. J Gastroenterol (2001) 2.17
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Recombinant human Fas ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits. Am J Physiol Lung Cell Mol Physiol (2001) 2.16
Functional assignment of the ORF2-iscS-iscU-iscA-hscB-hscA-fdx-ORF3 gene cluster involved in the assembly of Fe-S clusters in Escherichia coli. J Biochem (1999) 2.15
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med (1999) 2.13
Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 2.09
The relationship between facet joint osteoarthritis and disc degeneration of the lumbar spine: an MRI study. Eur Spine J (1999) 2.07
Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol (1999) 2.07
Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res (2002) 2.06
Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med (1999) 2.05
Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line, Jurkat. J Virol (1989) 2.03
Anomalous origin of the left coronary artery from the pulmonary artery. New operative technique. J Thorac Cardiovasc Surg (1993) 2.02
Walking speed as a good predictor for the onset of functional dependence in a Japanese rural community population. Age Ageing (2000) 1.99
Complete nucleotide sequence of the 26S rRNA gene of Physarum polycephalum: its significance in gene evolution. Proc Natl Acad Sci U S A (1983) 1.98
Temporary inhalation anaesthesia in experimental pigs. Lab Anim (2009) 1.98
Afadin: A key molecule essential for structural organization of cell-cell junctions of polarized epithelia during embryogenesis. J Cell Biol (1999) 1.96
Noggin is required for induction of the hair follicle growth phase in postnatal skin. FASEB J (2001) 1.95
Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Invest (1998) 1.95
Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J Immunol (1991) 1.92
MRI of cervical intervertebral discs in asymptomatic subjects. J Bone Joint Surg Br (1998) 1.92
Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene (1999) 1.91
Possible relationship of a 36-megadalton Salmonella enteritidis plasmid to virulence in mice. Infect Immun (1985) 1.91
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A (1999) 1.91
Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. Osteoarthritis Cartilage (2009) 1.90
Functional properties of channels formed by the neuronal gap junction protein connexin36. J Neurosci (1999) 1.90
Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol (2003) 1.89
Transplantation of human neural stem cells for spinal cord injury in primates. J Neurosci Res (2005) 1.88
Identification of two distinct elements in the long terminal repeat of HTLV-I responsible for maximum gene expression. EMBO J (1987) 1.88
Genetic studies of autoimmunity in New Zealand mice. III. Associations among anti-DNA antibodies, NTA, and renal disease in (NZB x NZW)F1 x NZW backcross mice. J Immunol (1981) 1.88